{"doi":"10.1002/hed.27359","title":"Impact of monoclonal antibody therapy for head and neck cancer on end‐of‐life care utilization and costs","abstract":"BACKGROUND: The impact of monoclonal antibody therapy (mAB) for advanced head and neck cancer on end-of-life health care utilization and costs has yet to be adequately studied. METHODS: Retrospective cohort study of patients aged 65 and over with a diagnosis of head and neck cancer between 2007 and 2017 within the SEER-Medicare registry assessing the impact of mAB therapy (i.e., cetuximab, nivolumab, or pembrolizumab) on end-of-life health care utilization (ED visits, inpatient admissions, ICU admissions, and hospice claims) and costs. RESULTS: Of 12 544 patients with HNC, 270 (2.2%) utilized mAB therapy at the end-of-life period. On multivariable analyses adjusting for demographic and clinicopathologic characteristics, there was a significant association between mAB therapy and emergency department visits (OR: 1.38, 95% CI: 1.1-1.8, p = 0.01) and healthcare costs (β: $9760, 95% CI: 5062-14 458, p < 0.01). CONCLUSIONS: mAB use is associated with higher emergency department utilization and health care costs potentially due to infusion-related and drug toxicity expenses.","journal":"Head & Neck","year":2023,"id":379564,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7762,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1144288,"name":"Pratyusha Yalamanchi","orcid":"0000-0003-0776-3759","position":1,"is_corresponding":false},{"id":65767,"name":"Jeremy M. G. Taylor","orcid":"0000-0003-2791-1229","position":2,"is_corresponding":false},{"id":363724,"name":"Nicholas R. Lenze","orcid":"0000-0002-2126-6663","position":3,"is_corresponding":false},{"id":383061,"name":"Francis P. Worden","orcid":"0000-0002-6632-4951","position":4,"is_corresponding":false},{"id":304744,"name":"Steven B. Chinn","orcid":"0000-0003-4282-0640","position":5,"is_corresponding":false},{"id":74090,"name":"Michelle Chen","orcid":"0000-0002-6988-5658","position":6,"is_corresponding":false},{"id":1056217,"name":"William J. Benjamin","orcid":"0000-0003-4116-7408","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T01:16:56.650289Z","pmid":"36976786","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}